Fundamental Analysis of LIPELLA PHARMACEUTICALS INC(NASDAQ:LIPO) stock

Fundamental Rating

Taking everything into account, LIPO scores 2 out of 10 in our fundamental rating. LIPO was compared to 565 industry peers in the Biotechnology industry. While LIPO seems to be doing ok healthwise, there are quite some concerns on its profitability. LIPO does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

LIPO had negative earnings in the past year.

In the past year LIPO has reported a negative cash flow from operations.

In the past 5 years LIPO always reported negative net income.

In the past 5 years LIPO always reported negative operating cash flow.

1.2 Ratios

LIPO has a Return On Assets of -189.66%. This is amonst the worse of the industry: LIPO underperforms 90.02% of its industry peers.

LIPO has a worse Return On Equity (-243.13%) than 71.84% of its industry peers.

		Industry Rank	Sector Rank
ROA	-189.66%
ROE	-243.13%
ROIC	N/A

ROA(3y)-88.49%

ROA(5y)-64.78%

ROE(3y)-111.16%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

LIPO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

LIPO does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for LIPO has been increased compared to 1 year ago.

There is no outstanding debt for LIPO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -9.63, we must say that LIPO is in the distress zone and has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -9.63, LIPO is doing worse than 74.33% of the companies in the same industry.

LIPO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-9.63

ROIC/WACCN/A

WACC10.58%

2.3 Liquidity

A Current Ratio of 4.33 indicates that LIPO has no problem at all paying its short term obligations.

With a Current ratio value of 4.33, LIPO perfoms like the industry average, outperforming 47.42% of the companies in the same industry.

LIPO has a Quick Ratio of 4.33. This indicates that LIPO is financially healthy and has no problem in meeting its short term obligations.

Looking at the Quick ratio, with a value of 4.33, LIPO is in line with its industry, outperforming 49.38% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	4.33
Quick Ratio	4.33

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 33.62% over the past year.

LIPO shows a strong growth in Revenue. In the last year, the Revenue has grown by 24.04%.

LIPO shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -22.39% yearly.

EPS 1Y (TTM)33.62%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%53.95%

Revenue 1Y (TTM)24.04%

Revenue growth 3Y-22.39%

Revenue growth 5YN/A

Sales Q2Q%27.89%

3.2 Future

The Earnings Per Share is expected to decrease by -64.53% on average over the next years. This is quite bad

LIPO is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -25.99% yearly.

EPS Next Y-483.29%

EPS Next 2Y-105.96%

EPS Next 3Y-64.53%

EPS Next 5YN/A

Revenue Next Year-36.03%

Revenue Next 2Y-41.42%

Revenue Next 3Y-25.99%

Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

LIPO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year LIPO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A cheap valuation may be justified as LIPO's earnings are expected to decrease with -64.53% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-105.96%

EPS Next 3Y-64.53%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

LIPO does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

LIPELLA PHARMACEUTICALS INC

NASDAQ:LIPO (11/18/2024, 8:00:02 PM)

After market: 2.5876 +0.28 (+12.02%)

2.31

-0.12 (-4.82%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap2.80M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-189.66%
ROE	-243.13%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.23

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	4.33
Quick Ratio	4.33
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)33.62%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y-483.29%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)24.04%

Revenue growth 3Y-22.39%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

LIPELLA PHARMACEUTICALS INC (LIPO)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens